Revolutionizing Global Healthcare with Decentralized Science (DeSci)
Affordable leverages innovative financial models to fund and validate cost-effective therapies, making healthcare accessible and affordable for all.
Partners
Join the movement to fund public good medicines and reduce healthcare costs globally.
What is Affordable?
Problem Statement
Rising global healthcare costs are unsustainable, leaving patients without access to essential medications.
Solution
Affordable tackles this issue by validating low-cost alternatives through financial models like IVPE (Interventional Pharmacoeconomics) and PFS (Pay-for-Success), incentivizing clinical trials funded by cost-savings or QALY improvements.
Affordable Therapy Rankings
IVPE Table
PFS Table
Medical Disclaimer:
The Affordable IVPE and Affordable PFS tables below are an example only and will be reviewed and validated by clinical advisors in Phase 2 of the project after the $AFF Token Sale. This is not a statement that the treatments listed are proven to be effective for the conditions mentioned. Links to the relevant research data will be provided where applicable.
These treatments should only be used under the oversight of a registered medical professional. Affordable does not make medical claims and encourages consulting healthcare professionals before considering any therapy.
Affordable IVPE Table
This table highlights therapies with potential for significant healthcare cost reductions through Interventional Pharmacoeconomics (IVPE). By identifying cost-effective alternatives to high-cost treatments, the table ranks candidates suitable for IVPE funding by health insurers based on their ability to deliver savings while maintaining or improving clinical outcomes. Therapies are evaluated using evidence probability, global patient population, and cost difference, with rankings driven by their potential to optimize healthcare spending.
| Affordable Algorithm Ranking | Therapy | Disease | Global Patient Population | Cost Difference ($) | Evidence Probability (Score: Evidence Type) | Annual Total Cost Reduction Potential ($) | PubMed Link |
|---|---|---|---|---|---|---|---|
| 0.70 | Pembrolizumab (Dose Reduction) | Lung Cancer | 1,000,000 | $90,000 (90% dose reduction; $100,000 baseline) | 0.6: Prospective Studies | 0.6: Prospective Studies $90 billion | Pembrolizumab Optimization |
| 0.70 | Rituximab | Rituximab Multiple Sclerosis | 2,800,000 | $72,000 (Ocrelizumab: $80,000) | 0.7: Phase 3 RCTs | $201.6 billion | Rituximab for MS |
| 0.70 | Ketamine | Treatment-Resistant Depression | 20,000,000 | $20,000 (Esketamine: $25,000) | 0.7: Phase 3 RCTs | $400 billion | Ketamine in TRD |
| 0.50 | Ketogenic Diet | Glioblastoma | 1,500,000 | $90,000 ($100,000 baseline) | 0.5: Prospective Studies | $135 billion | Ketogenic Diet for Cancer |
| 0.40 | Fluvoxamine | COVID-19 | 100,000,000 | $690 (Molnupiravir: $700) | 0.4: RCT Emulation | $69 billion | Fluvoxamine for COVID-19 |
Medical Disclaimer:
The Affordable IVPE and Affordable PFS tables below are an example only and will be reviewed and validated by clinical advisors in Phase 2 of the project after the $AFF Token Sale. This is not a statement that the treatments listed are proven to be effective for the conditions mentioned. Links to the relevant research data will be provided where applicable.
These treatments should only be used under the oversight of a registered medical professional. Affordable does not make medical claims and encourages consulting healthcare professionals before considering any therapy.
Affordable PFS Table
This table focuses on therapies with potential for QALY (Quality-Adjusted Life Year) impact, using evidence probability and global health needs to rank their health benefits. Unlike the IVPE table, this focuses on therapies without high-cost comparators where PFS contracts incentivize the funding of clinical studies and where QALY improvements drive funding priorities.
| Affordable Algorithm Ranking | Therapy | Disease | Annual Cost ($) | Evidence Probability (Score: Evidence Type) | Global Patient Population | Estimated QALY Impact (Millions) | PubMed Link |
|---|---|---|---|---|---|---|---|
| 0.70 | Metformin | Anti-aging, cancer prevention, cardiovascular | $48–$100 | 0.7: Observational Studies | 50,000,000 | 17.5 | MILES Study |
| 0.50 | Rapamycin | Cancer prevention, longevity | $48,500 | 0.4: RCT Emulation | 50,000,000 | 10.0 | Rapamycin in Aging |
| 0.40 | Paricalcitol | Pancreatic cancer, fibrosis modulation | $1,000–$2,000 | 0.4: Retrospective Studies | 500,000 | 0.2 | Paricalcitol in Pancreatic Cancer |
| 0.35 | Ulipristal Acetate (UPA) | Long-term uterine fibroid management | $500–$1,000 | 0.35: Limited Trials | 10,000,00 | 3.5 | UPA for Fibroids |
| 0.65 | Ketogenic Diet | Cancer, type 2 diabetes, neurological disorders | $500–$2,000 | 0.5: Prospective Studies | 1,500,000 | 0.75 | Ketogenic Diet for Cancer |
| 0.55 | Low-Dose Naltrexone | Autoimmune diseases, chronic pain, fibromyalgia | $30–$50 | 0.4: RCT Emulation | 20,000,000 | 8.0 | LDN in Inflammation |
| 0.50 | Aspirin (Low Dose) | Cancer prevention, Alzheimer’s, pre-eclampsia | $25–$50 | 0.5: Prospective Studie | 10,000,000 | 2.5 | Aspirin in Cancer Prevention |
| # | Drug/Supplement | Current Use | Potential Use | Evidence Gap | Annual Cost | Potential Savings | PubMed Link |
|---|---|---|---|---|---|---|---|
| 1 | Metformin | Diabetes (Type 2) | Anti-aging, cancer prevention, cardiovascular, neurodegeneration | Observational studies suggest benefits; RCTs needed | $48–$100 | Billions in age-related disease prevention | Metformin in Longevity Study (MILES) |
| 2 | Ketogenic Diet | Epilepsy | Cancer, type 2 diabetes, obesity, Alzheimer’s, Parkinson’s | Small-scale studies; long-term safety and efficacy data lacking | $500–$2,000 | Reduced chronic disease and medication costs | Ketogenic Diet in Neurological Disorders |
| 3 | Rituximab | B-cell cancers, autoimmune diseases | Chronic fatigue syndrome, type 1 diabetes | Small-scale studies; larger RCTs needed | $2,500–$6,000 | Lower costs of autoimmune disease management | Rituximab in CFS |
| 4 | Low-Dose Naltrexone | Opioid and alcohol addiction | Autoimmune diseases, chronic pain, fibromyalgia | Anecdotal evidence; larger clinical trials needed | $30–$50 | Reduced costs of managing chronic pain and autoimmune therapies | LDN in Inflammatory Conditions |
| 5 | Aspirin (Low Dose) | Cardiovascular prevention | Cancer prevention, Alzheimer’s, pre-eclampsia | Mixed trial results; further studies required | $25–$50 | Significant savings in cancer treatment and prevention | Aspirin in Cancer Prevention |
| 6 | Propranolol | Hypertension, anxiety, migraines | PTSD, cancer (angiogenesis inhibition) | Early evidence promising; large trials needed | $40–$80 | Reduced costs for mental health and cancer therapies | Propranolol in PTSD |
| 7 | Paricalcitol | Secondary hyperparathyroidism | Pancreatic cancer, fibrosis modulation | Preclinical studies show promise; more trials needed | $1,000–$2,000 | Enhanced effectiveness of cancer treatments | Paricalcitol and Pancreatic Cancer |
| 8 | Doxycycline | Antibiotic (acne, infections) | Arthritis, cancer, neurodegeneration | Small studies; robust trials required | $20–$40 | Reduced costs for anti-inflammatory and cancer drugs | Doxycycline and Inflammation |
| 9 | Famotidine | Acid reflux, heartburn | Long COVID, histamine-related conditions | Early data suggest potential; inconclusive | $30–$60 | Lower hospitalization costs for COVID-19 | Famotidine in COVID-19 |
| 10 | Ulipristal Acetate (UPA) | Emergency contraception, uterine fibroids | Long-term fibroid management | Safety concerns (e.g., liver toxicity); more safety data needed | $500–$1,000 | Reduced surgical costs and better fibroid outcomes | UPA for Fibroids |
| 11 | Ivermectin | Anti-parasitic | Antiviral (e.g., dengue, Zika), anti-inflammatory | Mixed results; controversial; needs rigorous trials | $20–$40 | Low-cost alternative for managing viral conditions | Ivermectin as Antiviral |
| 12 | Hydroxychloroquine | Malaria, lupus, rheumatoid arthritis | Anti-viral, cancer, autoimmune conditions | Limited evidence for newer uses; robust trials needed | $50–$100 | Cheaper alternatives for autoimmune conditions | HCQ in Autoimmune Diseases |
| 13 | Melatonin | Sleep aid | Cancer treatment, migraines, mood disorders | Promising early-phase studies; validation required | $25–$50 | Reduced reliance on sleep and mental health medications | Melatonin and Cancer |
| 14 | Glucosamine | Joint health supplement | Osteoarthritis, anti-inflammatory conditions | Conflicting data on efficacy; more robust trials needed | $200–$400 | Decreased use of NSAIDs and associated costs | Glucosamine in Osteoarthritis |
| 15 | Magnesium | Supplement for deficiency | Migraines, depression, blood pressure regulation | Limited large-scale trials | $30–$60 | Reduced costs of migraine and hypertension treatments | Magnesium for Migraines |
| 16 | Zinc | Immune booster, wound healing | Shorter cold duration, age-related macular degeneration | Small-scale studies; needs larger trials | $20–$40 | Reduced colds and healthcare visits | Zinc and Immunity |
| 17 | Berberine | Herbal medicine for diabetes and lipids | Cardiovascular protection, gut microbiome modulation | Promising early studies; larger RCTs needed | $120–$240 | Alternative to expensive diabetes drugs | Berberine in Diabetes |
| 18 | Vitamin D | Bone health and immune function | Cancer prevention, mood disorders, cardiovascular health | Strong associations; causative trials needed | $20–$50 | Prevention of fractures and chronic diseases | Vitamin D in Cancer |
| 19 | Selenium | Antioxidant, thyroid health | Cancer prevention, immune modulation | Mixed data; further research required | $15–$30 | Reduced thyroid and chronic disease costs | Selenium and Cancer |
| 20 | Coenzyme Q10 (CoQ10) | Heart health, mitochondrial support | Heart failure, migraines, neurodegenerative conditions | Early studies promising, but dose standardization unclear | $100–$300 | Reduced need for high-cost cardiac and neurological drugs | CoQ10 in Neuroprotection |
| 21 | Curcumin | Anti-inflammatory supplement | Arthritis, depression, certain cancers | Observational and pilot studies; larger trials needed | $100–$200 | Reduced dependence on anti-inflammatory medications | Curcumin and Inflammation |
| 22 | Probiotics | Gut health | Mental health, immune modulation, metabolic diseases | Variability in strains; standardization needed | $200–$400 | Decreased incidence of gut disorders and related costs | Probiotics and Depression |
| 23 | Melatonin | Sleep aid | Anti-cancer therapy adjunct, migraines, mood regulation | Preclinical and limited clinical data available | $25–$50 | Decreased reliance on costly insomnia treatments | Melatonin in Cancer |
| 24 | Spironolactone | Heart failure, hypertension | Polycystic ovary syndrome (PCOS), acne, hirsutism | Promising for hormonal regulation; more trials needed | $100–$200 | Reduced dependence on hormonal medications | Spironolactone in PCOS |
| 25 | Sulfasalazine | Rheumatoid arthritis, inflammatory bowel disease | Neuroprotection in ALS, chronic inflammation | Preliminary studies; needs broader evidence | $150–$300 | Cheaper alternative for inflammatory conditions | Sulfasalazine and ALS |
| 26 | Ashwagandha | Stress relief, adaptogen | Anxiety, depression, cognitive enhancement | Limited large-scale RCTs, mostly small trials | $150–$250 | Reduced costs for anxiety and cognitive treatments | Ashwagandha and Anxiety |
| 27 | Niacin | Dyslipidemia | Neuroprotection, arthritis, anti-aging | Promising preclinical data; limited trials in humans | $50–$150 | Reduced need for statins and inflammatory medications | Niacin for Neuroprotection |
| 28 | Inositol | PCOS, insulin resistance | Anxiety, depression, metabolic syndrome | Small-scale studies suggest benefits; more data needed | $100–$300 | Reduced reliance on antidepressants and metabolic drugs | Inositol in PCOS and Depression |
| 29 | Acetylcysteine (NAC) | Antioxidant, respiratory conditions | OCD, bipolar disorder, and substance use disorders | Early trials promising; definitive evidence lacking | $50–$150 | Cost savings for psychiatric and substance abuse treatments | NAC for OCD and Bipolar |
| 30 | Boswellia (Frankincense) | Anti-inflammatory supplement | Arthritis, inflammatory bowel disease (IBD) | Preclinical and small trials suggest promise; larger trials needed | $100–$200 | Reduced dependence on NSAIDs and IBD medications | Boswellia in Inflammatory Diseases |
| 31 | Green Tea Extract (EGCG) | Antioxidant, general health | Cancer prevention, neuroprotection, metabolic health | Promising in preclinical studies; human data limited | $150–$300 | Reduced healthcare costs related to neurodegeneration | Green Tea in Cancer Prevention |
| 32 | Resveratrol | Cardiovascular health | Anti-aging, neuroprotection, diabetes | Conflicting human data; more targeted RCTs needed | $200–$400 | Prevention of age-related and cardiovascular diseases | Resveratrol and Aging |
| 33 | Valproic Acid | Epilepsy, bipolar disorder | Alzheimer’s disease, migraine prevention | Early evidence of benefit; limited clinical trials | $100–$300 | Reduced Alzheimer’s-related healthcare costs | Valproic Acid in Alzheimer’s |
| 34 | Rifaximin | Hepatic encephalopathy, IBS | SIBO (small intestinal bacterial overgrowth) | Effective in IBS-related SIBO; wider utility needs research | $1,000–$1,500 | Reduced need for invasive IBS treatments | Rifaximin in IBS |
| 35 | Cimetidine | GERD, ulcers | Cancer adjunct (e.g., colorectal), warts | Case reports and small trials suggest anti-tumor effects; validation needed | $50–$100 | Low-cost adjunct to chemotherapy | Cimetidine for Cancer |
| 36 | L-Carnitine | Energy metabolism, supplementation | Fatigue, neurodegenerative diseases, cardiovascular health | Early data is promising; more definitive studies required | $100–$200 | Potential savings in managing chronic fatigue | L-Carnitine in Fatigue |
| 37 | Alpha-Lipoic Acid (ALA) | Antioxidant | Peripheral neuropathy, diabetes, neuroprotection | Small trials supportive; more studies needed | $50–$150 | Reduced costs of neuropathy and diabetes complications | ALA in Neuropathy |
| 38 | Bacopa Monnieri | Cognitive enhancer, adaptogen | ADHD, memory enhancement, neuroprotection | Small studies show benefit; larger RCTs required | $100–$300 | Reduced reliance on cognitive medications | Bacopa in ADHD |
| 39 | Taurine | Cardiovascular health, supplement | Neuroprotection, anxiety, diabetes | Promising in preclinical data; human trials sparse | $50–$100 | Decreased costs of treating anxiety and neurodegenerative disorders | Taurine in Neuroprotection |
| 40 | L-Theanine | Relaxation, stress relief | Anxiety, sleep enhancement | Early trials supportive; more robust human data needed | $50–$100 | Savings in treating sleep and anxiety disorders | L-Theanine and Anxiety |
| 41 | Vitamin K2 | Bone and cardiovascular health | Osteoporosis, arterial calcification prevention | Limited trials, but early evidence promising | $50–$150 | Reduced reliance on osteoporosis and cardiovascular drugs | Vitamin K2 in Osteoporosis |
| 42 | Ginger Extract | Anti-nausea, digestive aid | Anti-inflammatory, anti-cancer, metabolic syndrome | Promising preclinical studies; limited human trials | $50–$100 | Reduced reliance on anti-inflammatory medications | Ginger in Inflammation |
| 43 | Quercetin | Antioxidant | Allergies, cardiovascular health, anti-cancer effects | Early-phase clinical trials suggest promise; larger studies needed | $100–$200 | Cost-effective adjunct for cardiovascular health | Quercetin in Cardiovascular Health |
| 44 | Psyllium Husk | Digestive health, fiber supplement | Lowering cholesterol, improving metabolic health | Well-documented for cholesterol; broader metabolic applications need trials | $50–$150 | Savings on cholesterol-lowering drugs | Psyllium for Cholesterol |
| 45 | Black Seed Oil (Nigella) | Traditional medicine for inflammation | Cancer prevention, diabetes management, neuroprotection | Promising preclinical and pilot studies; robust human data lacking | $50–$100 | Reduced need for high-cost anti-inflammatory and metabolic drugs | Black Seed Oil and Cancer |
| 46 | Fenugreek | Lactation aid, traditional medicine | Diabetes, cholesterol management, testosterone boosting | Small studies support use; larger trials needed | $50–$150 | Cost-effective alternative to diabetes drugs | Fenugreek for Diabetes |
| 47 | Milk Thistle (Silymarin) | Liver protection | Antioxidant for liver diseases, cancer prevention | Early-phase data supports use; human trials limited | $50–$150 | Reduced liver disease management costs | Milk Thistle in Liver Health |
| 48 | Hyaluronic Acid | Joint injections, skincare | Oral treatment for osteoarthritis, dry eyes | Promising small trials; more data needed | $100–$300 | Savings on expensive joint treatments and eye medications | Hyaluronic Acid in Osteoarthritis |
| 49 | Choline | Cognitive health | Alzheimer’s prevention, liver protection, fetal brain health | Observational data strong; causative studies required | $50–$200 | Cost savings in managing Alzheimer’s and liver disease | Choline in Neuroprotection |
| 50 | Vitamin B6 (Pyridoxine) | Treats B6 deficiency, nausea | Depression, premenstrual syndrome, neuroprotection | Mixed results in small studies; more RCTs needed | $30–$50 | Reduced costs for antidepressants and PMS treatments | Vitamin B6 in Depression |
| 51 | Folic Acid | Prenatal health, anemia | Depression, cardiovascular health | Observational data strong; clinical trials sparse | $30–$50 | Lower costs in managing mental health and cardiovascular conditions | Folic Acid in Depression |
| 52 | Tryptophan | Dietary supplement for sleep | Anxiety, depression | Small clinical studies suggest promise; larger RCTs needed | $50–$100 | Reduced reliance on antidepressants | Tryptophan for Depression |
| 53 | GABA (Gamma-Aminobutyric Acid) | Stress relief, relaxation | Anxiety, sleep disorders | Early studies support use; definitive human studies required | $50–$150 | Cost-effective alternative to sedatives and anxiety medications | GABA and Anxiety |
| 54 | Rhodiola Rosea | Adaptogen for stress | Cognitive enhancement, depression, fatigue | Pilot studies supportive; larger trials needed | $150–$300 | Reduced dependence on antidepressants and energy stimulants | Rhodiola in Fatigue and Depression |
| 55 | Cannabidiol (CBD) | Seizures (e.g., Epidiolex) | Anxiety, sleep disorders, chronic pain | Promising data for anxiety and pain; dosing inconsistencies limit broader use | $500–$1,500 | Reduced need for opioids and anxiolytics | CBD in Anxiety and Pain |
| 56 | L-Arginine | Cardiovascular support, nitric oxide booster | Erectile dysfunction, hypertension, immune modulation | Promising small trials; larger studies needed | $50–$100 | Lower costs for ED and hypertension medications | L-Arginine for ED |
| 57 | Collagen Peptides | Skin and joint health | Osteoarthritis, wound healing, sarcopenia | Preclinical and small clinical trials support use | $200–$400 | Reduced use of joint pain and muscle repair treatments | Collagen in Osteoarthritis |
| 58 | Nicotinamide Riboside (NR) | Cellular repair, NAD+ booster | Anti-aging, neuroprotection, metabolic health | Mixed results in early trials; larger, targeted studies needed | $300–$600 | Savings in age-related disease management | Nicotinamide Riboside in Aging |
| 59 | Alpha-GPC (Glycerophosphocholine) | Cognitive enhancement, memory support | Alzheimer’s disease, stroke recovery | Limited clinical trials available | $200–$500 | Reduced dependence on Alzheimer’s medications | Alpha-GPC in Cognitive Decline |
| 60 | Hesperidin | Antioxidant, anti-inflammatory | Cardiovascular health, venous insufficiency | Promising in small trials; limited large-scale human data | $100–$200 | Reduced reliance on cardiovascular medications | Hesperidin in Cardiovascular Health |
| 61 | Astaxanthin | Antioxidant, skin health | Anti-aging, cardiovascular health, muscle recovery | Preclinical evidence strong; limited human trials | $150–$300 | Savings in age-related disease and recovery supplements | Astaxanthin in Cardiovascular Health |
| 62 | DHEA (Dehydroepiandrosterone) | Hormone replacement therapy, anti-aging | Cognitive health, depression, osteoporosis | Early clinical trials supportive; safety concerns at higher doses | $150–$300 | Reduced costs for osteoporosis and depression treatments | DHEA in Cognitive Decline |
| 63 | Chlorella | Algae-based supplement for detox | Heavy metal detoxification, cholesterol management | Pilot studies suggest benefits; robust data needed | $200–$400 | Reduced cholesterol management and detoxification costs | Chlorella in Detoxification |
| 64 | Elderberry (Sambucus) | Cold and flu prevention | Immune boosting, viral infection mitigation | Anecdotal and early-phase evidence; larger trials needed | $50–$150 | Reduced use of antiviral and immune-support medications | Elderberry in Viral Infections |
| 65 | SAM-e (S-Adenosyl Methionine) | Depression, liver support | Osteoarthritis, cognitive health, fibromyalgia | Promising in small trials; larger studies required | $300–$600 | Reduced antidepressant and arthritis treatment costs | SAM-e for Depression |
| 66 | Vitamin E (Tocopherol) | Antioxidant, skin health | Neuroprotection, cardiovascular health | Conflicting results in large-scale trials | $30–$50 | Savings in treating neurodegenerative diseases | Vitamin E in Alzheimer’s |
| 67 | Licorice Root Extract | Digestive health, traditional medicine | Immune modulation, hormonal regulation | Early studies suggest potential; safety at high doses a concern | $50–$150 | Reduced use of immune and hormonal therapies | Licorice and Immune Health |
| 68 | MSM (Methylsulfonylmethane) | Joint pain relief, skin health | Osteoarthritis, inflammation | Limited RCTs available; promising pilot studies | $100–$200 | Cost-effective alternative to joint pain medications | MSM for Osteoarthritis |
| 69 | Bromelain | Anti-inflammatory enzyme from pineapple | Post-surgical recovery, sinusitis | Promising in small trials; larger studies needed | $50–$150 | Reduced costs of post-surgical inflammation treatments | Bromelain for Sinusitis |
| 70 | Ginseng (Panax) | Energy, cognitive enhancer | Immune system modulation, fatigue | Preclinical and small trials suggest efficacy | $200–$400 | Lower costs for fatigue and cognitive performance treatments | Ginseng and Fatigue |
| 71 | Caprylic Acid | Supplement for gut health | Candida overgrowth, lipid metabolism | Limited clinical trials; early evidence promising | $100–$200 | Savings in managing fungal infections and gut issues | Caprylic Acid in Candida |
| 72 | Tribulus Terrestris | Libido enhancement, traditional medicine | Hormonal health, athletic performance | Small-scale trials suggest benefits; larger studies needed | $150–$300 | Reduced reliance on hormonal replacement therapies | Tribulus in Hormonal Health |
| 73 | Serrapeptase | Enzymatic anti-inflammatory | Chronic pain, respiratory health | Limited human data; preclinical studies show promise | $150–$300 | Reduced dependency on NSAIDs and respiratory treatments | Serrapeptase and Inflammation |
| 74 | Fisetin | Antioxidant, anti-inflammatory | Anti-aging, cognitive protection | Preclinical evidence strong; human studies limited | $100–$200 | Reduced need for anti-aging and cognitive treatments | Fisetin for Aging |
| 75 | Beetroot Powder | Nitric oxide booster | Blood pressure regulation, exercise performance | Early-phase clinical trials suggest efficacy | $50–$150 | Cost savings on hypertension and performance-enhancing drugs | Beetroot for Hypertension |
| 76 | Artichoke Extract | Digestive health, cholesterol support | Liver health, cognitive support | Early clinical trials promising; more robust studies needed | $50–$150 | Reduced liver disease and cholesterol-related healthcare costs | Artichoke in Liver Health |
| 77 | Ginkgo Biloba | Cognitive enhancement | Alzheimer’s, tinnitus, peripheral vascular disease | Mixed evidence in large trials; variability in dosages | $150–$300 | Reduced need for cognitive and vascular treatments | Ginkgo in Cognitive Health |
| 78 | Moringa Oleifera | Nutritional supplement | Anti-inflammatory, diabetes management, cholesterol reduction | Promising preclinical data; limited clinical trials | $100–$200 | Lower costs for metabolic and inflammatory conditions | Moringa in Metabolic Health |
| 79 | Cranberry Extract | UTI prevention | Kidney health, bacterial infections | Small trials support use; further RCTs needed | $50–$150 | Reduced antibiotic use for UTIs | Cranberry in UTI Prevention |
| 80 | Dandelion Root | Digestive and liver health | Diuretic, anti-inflammatory | Preliminary evidence suggests benefits; larger studies needed | $50–$100 | Cost-effective alternative to diuretics and liver health drugs | Dandelion Root in Health |
| 81 | Andrographis Paniculata | Traditional anti-inflammatory | Respiratory infections, immune modulation | Pilot studies promising; larger trials required | $100–$200 | Reduced reliance on respiratory and immune system treatments | Andrographis in Respiratory Health |
| 82 | Cissus Quadrangularis | Bone health, traditional medicine | Osteoporosis, joint pain | Limited clinical data; promising in pilot studies | $100–$200 | Lower costs for osteoporosis and joint pain treatments | Cissus for Bone Health |
| 83 | Berberine (Expanded) | Gut and metabolic health | Cancer prevention, antimicrobial | Preclinical evidence for antimicrobial effects; human studies limited | $120–$240 | Savings in cancer prevention and infections | Berberine in Cancer |
| 84 | Shilajit | Adaptogen, traditional medicine | Anti-aging, cognitive health, metabolic support | Limited evidence from clinical trials; more robust research needed | $150–$300 | Reduced aging-related healthcare costs | Shilajit in Health |
| 85 | Valerian Root | Sleep aid, anxiety relief | Insomnia, stress | Evidence inconsistent across trials | $50–$150 | Savings on insomnia and sedative medications | Valerian for Sleep |
| 86 | Holy Basil (Tulsi) | Traditional stress reliever | Anxiety, immune support, metabolic health | Early evidence promising; larger-scale studies required | $100–$200 | Reduced costs for anxiety and immune health treatments | Holy Basil in Stress Relief |
| 87 | Cordyceps Sinensis | Energy and immune modulation | Chronic fatigue, exercise performance | Preclinical data strong; limited clinical trials | $200–$400 | Reduced costs for fatigue and energy supplementation | Cordyceps for Energy |
| 88 | Echinacea | Immune booster | Viral infections, wound healing | Evidence inconsistent in preventing colds and flu | $50–$150 | Cost-effective alternative for viral infection treatments | Echinacea in Viral Infections |
| 89 | Ashwagandha (Expanded) | Stress relief, adaptogen | Hormonal balance, physical performance | Larger RCTs needed for hormonal applications | $150–$300 | Reduced costs for stress and hormonal treatments | Ashwagandha and Hormonal Health |
| 90 | Grape Seed Extract | Antioxidant, cardiovascular health | Cancer prevention, neuroprotection | Preclinical data strong; human evidence limited | $100–$200 | Lower costs for cancer prevention and brain health treatments | Grape Seed in Neuroprotection |
| 91 | L-Tyrosine | Neurotransmitter precursor | Depression, ADHD, cognitive performance | Early evidence suggests benefit; needs more robust studies | $50–$150 | Cost-effective alternative to cognitive-enhancing medications | Tyrosine in Cognitive Function |
| 92 | Fenbendazole | Anti-parasitic (veterinary use) | Cancer adjunct | Anecdotal reports and preclinical studies; human evidence sparse | $20–$50 | Reduced costs in adjunct cancer therapies | Fenbendazole in Cancer |
| 93 | Saffron | Culinary spice, mood booster | Depression, Alzheimer’s, vision health | Promising data for depression; larger-scale RCTs required | $200–$400 | Savings on antidepressants and vision-related therapies | Saffron in Depression |
| 94 | Pomegranate Extract | Antioxidant, cardiovascular health | Cancer prevention, arthritis | Promising in preclinical studies; human trials needed | $150–$300 | Cost-effective adjunct for cancer and arthritis treatments | Pomegranate in Arthritis |
| 95 | Vitamin B12 | Anemia, B12 deficiency | Cognitive health, depression | Observational data strong; limited large-scale trials | $50–$100 | Reduced costs for managing anemia and mental health | Vitamin B12 and Cognition |
| 96 | Taurine (Expanded) | Supplement for energy | Anti-aging, cognitive health | Promising early-phase studies; needs targeted RCTs | $50–$150 | Lower costs for cognitive and energy treatments | Taurine in Anti-Aging |
| 97 | Baicalein (Scutellaria) | Traditional anti-inflammatory | Neuroprotection, cancer prevention | Early-phase studies show promise; needs further research | $100–$300 | Reduced dependence on anti-cancer and neuroprotective drugs | Baicalein for Neuroprotection |
| 98 | Chaga Mushroom | Immune booster, antioxidant | Cancer prevention, gastrointestinal health | Preclinical evidence strong; human trials sparse | $200–$400 | Lower costs for immune and cancer-preventative therapies | Chaga in Immune Health |
| 99 | Pea Protein | Dietary protein source | Weight management, muscle recovery | Early-phase evidence supports metabolic benefits | $100–$200 | Savings in weight and muscle-related treatments | Pea Protein in Metabolism |
| 100 | Bitter Melon (Momordica) | Traditional medicine for diabetes | Blood sugar control, cholesterol regulation | Preclinical and small trials promising; larger studies required | $50–$150 | Reduced reliance on diabetes medications | Bitter Melon in Diabetes |
| 101 | Cannabis Flower/THC | Chronic pain, nausea relief | Neuropathic pain, PTSD, anxiety | Mixed results in trials; dose standardization needed | $1,000–$3,000 | Reduced opioid dependency and chronic pain management costs | Cannabis for Chronic Pain |
| 102 | THC-CBD Combination | Epilepsy (via Epidiolex), pain management | Cancer pain, spasticity, sleep disorders | Promising trials; broader trials needed for combined formulations | $2,000–$5,000 | Reduced opioid use for cancer and chronic pain | THC-CBD in Cancer Pain |
| 103 | Vitamin C (High Dose) | Antioxidant, immune support | Sepsis, cancer adjunct, immune modulation | Limited evidence for high-dose intravenous use in cancer and sepsis | $100–$300 | Lower costs for sepsis and immune-related therapies | Vitamin C for Sepsis |
| 104 | Zinc (Expanded) | Immune booster | Viral infections (e.g., COVID-19), wound healing | Early-phase studies suggest promise; larger trials needed | $30–$50 | Reduced hospitalizations from infections | Zinc for COVID-19 |
| 105 | Ashwagandha (Expanded) | Stress and cortisol regulation | Hormonal health, anti-aging | Promising RCTs in cortisol reduction; long-term effects unclear | $150–$300 | Reduced healthcare costs for hormonal imbalance treatments | Ashwagandha for Cortisol |
| 106 | Erythropoietin (EPO) | Anemia (renal failure) | Stroke recovery, cognitive health | Preclinical studies suggest benefits; risks at high doses | $5,000–$10,000 | Reduced rehabilitation costs for stroke patients | Erythropoietin for Stroke |
| 107 | B12 + Folate Combination | Anemia, neural tube defect prevention | Depression, cognitive health | Promising in small trials; broader studies required | $50–$150 | Savings on antidepressants and mental health drugs | B12 and Folate in Depression |
| 108 | Turmeric/Curcumin (Expanded) | Anti-inflammatory supplement | Arthritis, cancer, cardiovascular disease | Small RCTs promising for inflammation; more robust trials needed | $100–$200 | Lower costs for inflammatory disease treatments | Curcumin in Arthritis |
| 109 | Cordyceps (Expanded) | Energy support | Athletic performance, immune modulation | Preclinical evidence strong; more human trials required | $200–$400 | Reduced need for performance-enhancing and immune drugs | Cordyceps in Athletic Performance |
| 110 | Choline (Expanded) | Brain health, prenatal support | Neuroprotection, liver health | Promising data in Alzheimer’s; further trials needed | $50–$200 | Reduced Alzheimer’s-related healthcare costs | Choline in Neurodegeneration |
| 111 | Kava Root Extract | Stress and anxiety relief | Insomnia, generalized anxiety disorder (GAD) | Limited RCTs; concerns about hepatotoxicity | $100–$300 | Cost-effective alternative to sedative medications | Kava for Anxiety |
| 112 | Peppermint Oil | IBS symptom relief | Headache relief, muscle relaxation | Pilot studies promising; broader RCTs needed | $50–$150 | Reduced dependence on antispasmodics and pain relief drugs | Peppermint Oil in IBS |
| 113 | Fenbendazole (Expanded) | Anti-parasitic (veterinary use) | Cancer adjunct therapy | Anecdotal evidence and preclinical studies; limited human trials | $20–$50 | Reduced costs for adjunct cancer therapies | Fenbendazole for Cancer |
| 114 | Lemon Balm | Stress relief, sleep aid | Cognitive health, anxiety reduction | Promising small studies; larger RCTs required | $50–$150 | Savings in managing anxiety and mild cognitive impairment | Lemon Balm in Cognitive Health |
| 115 | Blueberry Extract | Antioxidant, brain health | Neuroprotection, vision support | Early-phase studies promising; larger-scale human trials needed | $100–$300 | Reduced costs for cognitive and vision health | Blueberry in Neuroprotection |
| 116 | Sea Buckthorn Oil | Skin and mucosal health | Cardiovascular health, anti-aging | Limited human studies; needs more robust clinical evidence | $150–$300 | Reduced aging-related healthcare costs | Sea Buckthorn Oil for Skin |
| 117 | Beta-Alanine | Athletic performance | Muscle endurance, chronic fatigue | Promising in early trials; long-term safety data sparse | $100–$300 | Reduced costs for performance-enhancing supplements | Beta-Alanine in Performance |
| 118 | Mucuna Pruriens | Traditional use for Parkinson’s | Dopamine precursor for mood, neuroprotection | Limited RCTs; early-phase data supportive | $100–$200 | Cost-effective alternative to synthetic dopamine precursors | Mucuna Pruriens for Parkinson’s |
| 119 | Caralluma Fimbriata | Appetite suppressant | Obesity management, metabolic syndrome | Small trials suggest benefits; broader studies needed | $150–$300 | Reduced reliance on anti-obesity drugs | Caralluma for Obesity |
| 120 | Hops Extract | Sleep aid, relaxation | Insomnia, anxiety relief | Limited clinical trials; more robust evidence required | $50–$150 | Savings on sedative and anxiety treatments | Hops Extract for Sleep |
| 121 | Palmitoylethanolamide (PEA) | Chronic pain relief | Neuropathic pain, inflammatory conditions | Promising in small trials; larger human studies required | $200–$500 | Reduced opioid dependency and chronic pain management costs | PEA in Chronic Pain |
| 122 | Licorice Root (Expanded) | Digestive health, traditional medicine | Hormonal health, respiratory support | Promising small studies; more safety data needed | $50–$150 | Reduced costs for hormonal imbalance and respiratory treatments | Licorice Root in Health |
| 123 | Celastrol | Traditional anti-inflammatory | Cancer prevention, neuroprotection | Preclinical evidence strong; human trials limited | $200–$400 | Reduced reliance on expensive cancer and neuroprotective drugs | Celastrol for Inflammation |
| 124 | Boswellia Serrata (Expanded) | Joint and inflammatory health | Cancer adjunct, IBD | Preclinical studies promising; more robust trials needed | $100–$300 | Cost savings for inflammation and IBD treatments | Boswellia in IBD |
| 125 | Coconut Oil | Cooking oil, skin moisturizer | Alzheimer’s management, metabolic syndrome | Early-phase studies suggest benefits; larger trials required | $100–$200 | Lower costs for Alzheimer’s-related and metabolic treatments | Coconut Oil in Alzheimer’s |
| 126 | Nigella Sativa (Expanded) | Immune modulation, antioxidant | Cardiovascular health, metabolic syndrome | Limited clinical trials; promising preclinical studies | $50–$100 | Savings in managing cardiovascular and metabolic conditions | Nigella Sativa in Cardiovascular Health |
| 127 | Eucalyptus Oil | Respiratory health, decongestant | Pain relief, wound healing | Preclinical evidence supports use; human trials limited | $50–$150 | Reduced costs for pain relief and wound management | Eucalyptus Oil in Pain Relief |
| 128 | Shiitake Mushroom Extract | Immune modulation | Cancer prevention, cholesterol management | Early-phase trials promising; broader studies needed | $100–$300 | Savings on cancer prevention and cholesterol-lowering treatments | Shiitake in Immune Health |
| 129 | Bitter Orange Extract | Energy booster, weight management | Athletic performance, fat loss | Small trials support use; safety concerns at higher doses | $100–$300 | Lower costs for weight loss and energy supplementation | Bitter Orange for Weight Loss |
| 130 | Resveratrol (Expanded) | Cardiovascular health, antioxidant | Longevity, neuroprotection | Limited large-scale human trials | $200–$400 | Reduced costs in age-related disease management | Resveratrol in Longevity |
| 131 | Ginger Root (Expanded) | Nausea relief, digestive health | Anti-inflammatory, cardiovascular health | Early clinical trials promising; more robust studies needed | $50–$150 | Savings in managing inflammation and cardiovascular conditions | Ginger in Cardiovascular Health |
| 132 | Marshmallow Root | Digestive and respiratory health | Cough relief, skin irritation | Preliminary evidence promising; larger trials required | $50–$150 | Reduced dependence on cough suppressants and topical treatments | Marshmallow Root in Respiratory Health |
| 133 | White Willow Bark | Pain relief, traditional NSAID precursor | Osteoarthritis, inflammatory conditions | Small trials suggest benefits; safety at higher doses needs study | $100–$300 | Cost-effective alternative to NSAIDs | White Willow for Pain Relief |
| 134 | Bacillus Coagulans | Probiotic for gut health | IBS, metabolic syndrome | Limited clinical trials; promising pilot studies | $100–$200 | Savings on gut health and metabolic treatments | Bacillus Coagulans in IBS |
| 135 | Lutein | Vision support | Macular degeneration, cognitive health | Observational evidence strong; causative trials required | $100–$200 | Reduced costs for vision-related healthcare | Lutein in Eye Health |
| 136 | Alpha-Tocopherol (Vitamin E) | Antioxidant | Cardiovascular protection, neuroprotection | Mixed results in trials; requires more focused studies | $50–$150 | Reduced reliance on cardiovascular and neuroprotective treatments | Vitamin E in Cardiovascular Health |
| 137 | Chromium Picolinate | Blood sugar regulation, insulin sensitivity | Type 2 diabetes, metabolic syndrome | Promising small trials; long-term efficacy unclear | $50–$150 | Cost savings for diabetes and metabolic drug treatments | Chromium in Diabetes |
| 138 | Cat’s Claw | Traditional immune booster | Inflammatory diseases, neuroprotection | Pilot studies promising; larger RCTs required | $100–$300 | Reduced reliance on inflammatory and neuroprotective treatments | Cat’s Claw in Inflammation |
| 139 | Evening Primrose Oil | Skin and hormonal health | PMS, eczema, arthritis | Mixed evidence in trials; requires more standardized studies | $150–$300 | Savings on PMS and skin-related healthcare treatments | Evening Primrose in PMS |
| 140 | Spirulina | Algae-based superfood | Immune health, cardiovascular support | Early studies suggest benefits; larger-scale research required | $200–$400 | Reduced costs for immune support and cardiovascular health | Spirulina in Cardiovascular Health |
| 141 | Tryptophan (Expanded) | Mood regulation, sleep enhancement | Depression, anxiety | Limited trials available; promising preclinical data | $50–$150 | Reduced antidepressant and anxiolytic use | Tryptophan in Depression |
| 142 | Reishi Mushroom | Immune modulation | Cancer adjunct, cardiovascular health | Strong preclinical evidence; limited human trials | $200–$400 | Lower costs for immune and cardiovascular therapies | Reishi in Immune Health |
| 143 | Hyaluronic Acid (Expanded) | Joint injections, skincare | Oral treatments for arthritis, wound healing | Preclinical studies promising; larger RCTs needed | $100–$300 | Reduced joint replacement and wound care costs | Hyaluronic Acid for Arthritis |
| 144 | DMAE (Dimethylaminoethanol) | Cognitive enhancer | ADHD, memory enhancement | Limited clinical trials; pilot studies promising | $100–$200 | Savings on cognitive and ADHD medications | DMAE in Cognitive Health |
| 145 | Pycnogenol (Pine Bark Extract) | Cardiovascular and antioxidant support | ADHD, varicose veins, inflammation | Early trials promising; larger-scale studies needed | $200–$500 | Reduced costs in ADHD and cardiovascular health management | Pycnogenol in ADHD |
| 146 | Flaxseed Oil | Omega-3 fatty acid supplement | Cardiovascular health, inflammation | Observational studies supportive; causative data limited | $100–$200 | Reduced healthcare costs for cardiovascular and inflammatory diseases | Flaxseed Oil in Health |
| 147 | B3 (Niacinamide, Expanded) | Skin health, cholesterol regulation | Neuroprotection, anti-aging | Promising small trials; long-term data sparse | $50–$150 | Cost-effective alternative to high-cost neuroprotective drugs | Niacinamide in Neuroprotection |
| 148 | Manuka Honey | Wound healing, antibacterial | Digestive health, skin infections | Small trials promising; requires standardization | $200–$400 | Reduced use of antibiotics for skin and wound infections | Manuka Honey in Wound Care |
| 149 | Carnosine | Antioxidant, anti-aging | Cognitive enhancement, neuroprotection | Preclinical evidence strong; limited human trials | $150–$300 | Reduced reliance on cognitive enhancement drugs | Carnosine in Aging |
| 150 | Kratom | Pain relief, traditional medicine | Chronic pain, opioid withdrawal | Promising in pilot studies; safety concerns require further study | $200–$500 | Reduced opioid use and chronic pain treatment costs | Kratom for Pain Relief |
Submit Evidence to Validate Affordable Therapies
Encourage users to propose therapies or share PubMed links for validation.
Explain that validated contributions earn $AFF tokens.
Affordable Tokenomics ($AFF)
Affordable tokens ($AFF) are used to incentivize collaboration and fund validation studies.
Benefits of $AFF:
Milestone-based payments for trials.
Incentives for community participation.
Vote on Affordable Therapies and Disease Areas to clinically-validate.
Contact Us
Short description encouraging inquiries from researchers, insurers, and contributors.
Email Contact: